Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nanjing Geneleap Biotechnology Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, yet they both fall within 1 distinct art unit. This indicates that while different individuals are conducting the reviews, they are doing so under the same supervisory and technical framework of a single art unit.
GALSTER, SAMUEL LEONARD is the busiest examiner for the company, managing 1 pending office action. This accounts for 1 of the 2 total pending office actions currently active. Having 2 distinct examiners in 1 distinct art unit can be advantageous, as it may lead to more consistent procedural outcomes while still providing two separate channels for technical advocacy. However, the company must still address the individual preferences of each examiner within that shared art unit environment to move the 2 pending actions toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18170512 | A 5'-CAP ANALOG MODIFIED mRNA | GALSTER, SAMUEL LEONARD | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18170512 | A 5'-CAP ANALOG MODIFIED mRNA | GALSTER, SAMUEL LEONARD | 22d overdue |
| 17689895 | GALNAC CLUSTER PHOSPHORAMIDITE AND TARGETED THERAPEUTIC NUCLEOSIDES | CHO, DAVID H | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18170512 | A 5'-CAP ANALOG MODIFIED mRNA | GALSTER, SAMUEL LEONARD | 1693 | §103§112 | Final Rejection | 22d overdue | Pending | Feb 16, 2023 |
| 17689895 | GALNAC CLUSTER PHOSPHORAMIDITE AND TARGETED THERAPEUTIC NUCLEOSIDES | CHO, DAVID H | 1693 | §103Other | Non-Final OA | — | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial